Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Sponsor
Sichuan Academy of Medical Sciences
Study ID
NCT06398977
Status
Recruiting
Apply to this trial

Conditions

  • Peritoneal Dialysis Complication
  • Renal Function Aggravated
  • Sodium-glucose Co-transporter-2 Inhibitors

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.

Key Dates

Start date
Mar 11, 2024
Status verified
Apr 2024
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: Dagliflozin group
    Patients in this group were treated with dagliflozin 10 mg, oral once daily, for 24 weeks, in addition to receiving basic treatments such as peritoneal dialysis and antihypertensive and hypoglycemic therapy.
  • No Intervention: Control group
    This group of patients received peritoneal dialysis and basic treatments such as antihypertensive and hypoglycemic therapy.

Primary Outcome Measure

Change in 24 urine volume [ Time Frame: Baseline, 2,12 and 24 weeks. ]

Central Contacts

Related Studies